Hennion & Walsh Asset Management Inc. Decreases Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Hennion & Walsh Asset Management Inc. decreased its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 9.5% in the third quarter, Holdings Channel.com reports. The institutional investor owned 12,625 shares of the company’s stock after selling 1,325 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Apellis Pharmaceuticals were worth $364,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. Fiera Capital Corp increased its position in shares of Apellis Pharmaceuticals by 47.7% during the 2nd quarter. Fiera Capital Corp now owns 1,401,190 shares of the company’s stock valued at $53,750,000 after purchasing an additional 452,753 shares during the last quarter. Iron Triangle Partners LP purchased a new stake in shares of Apellis Pharmaceuticals during the 1st quarter valued at about $32,329,000. Bank of New York Mellon Corp increased its position in shares of Apellis Pharmaceuticals by 6.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 345,195 shares of the company’s stock valued at $13,242,000 after purchasing an additional 22,273 shares during the last quarter. Altitude Crest Partners Inc. increased its position in shares of Apellis Pharmaceuticals by 88.7% during the 1st quarter. Altitude Crest Partners Inc. now owns 287,277 shares of the company’s stock valued at $16,886,000 after purchasing an additional 135,077 shares during the last quarter. Finally, AQR Capital Management LLC increased its position in shares of Apellis Pharmaceuticals by 337.3% during the 2nd quarter. AQR Capital Management LLC now owns 246,880 shares of the company’s stock valued at $9,177,000 after purchasing an additional 190,420 shares during the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Insider Transactions at Apellis Pharmaceuticals

In related news, Director A. Sinclair Dunlop sold 37,000 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the sale, the director now owns 100,000 shares in the company, valued at approximately $3,623,000. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 6.80% of the company’s stock.

Wall Street Analysts Forecast Growth

APLS has been the subject of several research reports. Wedbush upped their price target on shares of Apellis Pharmaceuticals from $38.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, August 9th. HC Wainwright cut their price objective on Apellis Pharmaceuticals from $92.00 to $83.00 and set a “buy” rating for the company in a research note on Friday, August 2nd. Wells Fargo & Company cut their price objective on Apellis Pharmaceuticals from $47.00 to $43.00 and set an “equal weight” rating for the company in a research note on Tuesday, September 24th. Needham & Company LLC reiterated a “buy” rating and set a $85.00 price objective on shares of Apellis Pharmaceuticals in a research note on Friday, September 20th. Finally, Scotiabank initiated coverage on Apellis Pharmaceuticals in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $35.00 price objective for the company. Five investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $65.41.

Apellis Pharmaceuticals Stock Up 0.3 %

Shares of APLS opened at $27.41 on Wednesday. The stock has a market capitalization of $3.33 billion, a price-to-earnings ratio of -7.92 and a beta of 0.87. Apellis Pharmaceuticals, Inc. has a 1 year low of $26.28 and a 1 year high of $73.80. The business’s 50 day simple moving average is $32.99 and its 200-day simple moving average is $38.18. The company has a debt-to-equity ratio of 1.73, a current ratio of 5.08 and a quick ratio of 4.18.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.03. The business had revenue of $199.70 million for the quarter, compared to analysts’ expectations of $190.89 million. Apellis Pharmaceuticals had a negative return on equity of 138.32% and a negative net margin of 52.99%. The company’s revenue for the quarter was up 110.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.02) EPS. As a group, equities analysts expect that Apellis Pharmaceuticals, Inc. will post -1.37 earnings per share for the current fiscal year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).